insulin secretagogues

Glimeripide - Linagliptin - Mitiglinide - Repaglinide      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

diabetes type 2

alogliptin
Seino, 2011      NCTalogliptin -
Seino, 2011     alogliptin -
Bosi , 2011      NCTalogliptin -
Kaku, 2011     alogliptin -
Rosenstock, 2010      NCTalogliptin -
Rosenstock, 2009      NCTalogliptin -
Pratley, 2009      NCTalogliptin -
Pratley, 2009      NCTalogliptin -
DeFronzo , 2008      NCTalogliptin -
EXAMINE, 2011        NCTalogliptinplacebonegative
Nauck, 2009      NCTalogliptinplacebo (add on MET)Low risk of bias negative
gliclazide
Ristic, 2006       gliclazidenateglinide (add on MET)Low risk of bias -
Matthews, 2005     gliclazidepioglitazone (add on MET)Low risk of bias -
Khanolkar, 2008     gliclaziderosiglitazone (add on MET) -
glimepiride
Charpentier, 2001     glimepiride monotherapymetforminLow risk of bias -
glimeripide
Study 201 (Goldberg), 1996   glimepirideplaceboLow risk of bias -
Schade, 1998   glimepirideplaceboLow risk of bias -
Rosenstock, 1996   glimepirideplaceboLow risk of bias -
Luis Bautista, 2003   glimepirideplaceboLow risk of bias -
Kaneko, 1993   glimepirideplacebo -
Study 202   glimepirideplacebo -
Riddle, 1994   glimepirideplacebo (add on insulin) -
LEAD-2 (Nauck) Sulf vs pbo, 2009      NCTglimepirideplacebo (add on MET)Low risk of bias -
Charpentier, 2001     glimepirideplacebo (add on MET)Low risk of bias negative
Draeger, 1996     glimepirideglibenclamideLow risk of bias -
Protocol 311   glimepirideglibenclamide -
Charpentier (301F)   glimepiridegliclazide -
Inukai, 2005     glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997   glimepiride odglimepiride bid -
Clark (301), 1997   glimepirideglipizide -
Dills, 1996   glimepirideglyburideLow risk of bias -
glipizide
Goldstein   glipizidecontrol (add on MET) -
Rosenstock, 1993   glipizideglyburide -
Birkeland, 1994   glipizideglyburide -
Birkeland, 1994   glipizideglyburideLow risk of bias -
Simonson, 1997   glipizideplaceboLow risk of bias -
Testa, 1998   glipizideplacebo -
Feinglos, 2005     glipizide GITSplacebo (add on MET)Low risk of bias -
Nauck, 2007     glipizidesitagliptin (add on MET) -
glyburide
Hermann, 1991   glibenclamidec (add on MET) -
DeFronzo, 1995   glyburidec (add on MET)Low risk of bias -
Erle, 1999   glyburidec (add on MET) -
Marre (ass), 2002   glibenclamidecontrol (add on MET)Low risk of bias -
Tosi, 2003   glibenclamidecontrol (add on MET)Low risk of bias -
Blonde, 2002   glyburidecontrol (add on MET)Low risk of bias -
Garber, 2003   glyburidecontrol (add on MET) -
Garber, 2002   glyburideplaceboLow risk of bias -
Vray, 1995   glyburideplaceboLow risk of bias -
Garber, 2006     glibenclamiderosiglitazone (add on MET)Low risk of bias -
linagliptin
Forst, 2010      NCTlinagliptinLow risk of bias -
CAROLINA, 2012      NCTlinagliptinglimepirideLow risk of bias suggesting
Gallwitz, 2012      NCTlinagliptinglimepiride (add on MET)Low risk of bias -
Owens      NCTlinagliptinMetformin + sulfonylurea -
Del Prato      NCTlinagliptinplaceboLow risk of bias -
Taskinen      NCTlinagliptinplacebo (add on MET) -
Gomis, 2011      NCTlinagliptinplacebo (add on pioglitazone) -
Lewin, 2010    NCTlinagliptinplacebo (add on SU)Low risk of bias -
mitiglinide
Gao      NCTmitiglinidenateglinideLow risk of bias -
Kumashiro, 2007     mitiglinideon top insulin glargine -
Kaku, 2009     mitiglinideplacebo (on top pioglitazone) -
nateglinide
Marre, 2002     nateglinideplaceboLow risk of bias -
Horton, 2000   nateglinideplaceboLow risk of bias -
Hanefeld, 1990   nateglinideplaceboLow risk of bias -
Saloranta, 2002   nateglinideplaceboLow risk of bias -
Mari, 2005   nateglinideplacebo -
Moses, 2001   nateglinideplaceboLow risk of bias -
Goldberg, 1998   repaglinideplaceboLow risk of bias -
Jovanovic, 2000   repaglinideplaceboLow risk of bias -
Bech, 2003   repaglinideplaceboLow risk of bias -
Li, 2009   nategliniderepaglinide -
Li, 2007   nategliniderepaglinide -
Ristic, 2006       nateglinidegliclazide (add on MET)Low risk of bias -
repaglinide
Moses, 1999     repaglinidecontrol (add on MET)Exploratory -
Landgraf, 1999   repaglinideglibenclamideLow risk of bias -
Marbury, 1999   repaglinideglibenclamide -
Wolffenbuttel, 1999   repaglinideglibenclamideLow risk of bias -
Madsbad, 2001   repaglinideglipizideLow risk of bias -
Lund, 2007   repaglinidemetforminLow risk of bias -
Raskin, 2001   repaglinideon top pioglitazone -
Raskin, 2001   repaglinideon top rosiglitazone -
Raskin, 2000   repaglinideon top troglitazone -
Chuang, 1999   repaglinideplacebo -
Goldberg, 1998   repaglinideplaceboExploratory -
Jovanovic, 2000   repaglinideplaceboLow risk of bias -
Landin-Olsson, 1999   repaglinideplacebo (on top bedtime NPH-insulin) -
saxagliptin
Kawamori, 2012        NCTsaxagliptin -
Forst, 2011   Saxagliptin -
Fonseca, 2012      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Yang, 2011      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Göke, 2010     saxagliptin -
Scheen , 2010     saxagliptin -
Stenlöf , 2010     Saxagliptin -
CV181-040      NCTsaxagliptin + glyburideglyburide uptitration -
CV181-085    NCTsaxagliptin plus metformin XR 1500mgmetformin up to 2000mg -
SAVOR-TIMI 53, 2013        NCTsaxagliptinplacebonegative
saxgliptin, renal study   saxagliptinplacebo (add on current treatment) -
CV181-057    NCTsaxagliptinplacebo (add on insulin) -
DeFronzo, 2009      NCTsaxagliptinplacebo (add on MET)negative
Jadzinsky, 2009      NCTsaxagliptinplacebo (add on MET) -
CV181-066    NCTsaxagliptinplacebo (add on MET) -
CV181-080    NCTsaxagliptinplacebo (add on MET) -
Hollander      NCTsaxagliptinplacebo (add on TZD) -
Rosenstock, 2008    NCTsaxagliptinplacebo (monotherapy) -
CV181-011      NCTsaxagliptinplacebo (monotherapy) -
CV181-038    NCTsaxagliptinplacebo (monotherapy) -
CV181-041    NCTsaxagliptinplacebo (monotherapy) -
saxagliptin vs sitagliptin   saxagliptinsitagliptin (add on MET) -
saxagliptin   saxagliptinglipizideLow risk of bias -
sitagliptin
Stafford , 2011      NCTsitagliptin -
Reasner, 2011      NCTsitagliptincontrol (add on MET) -
Arechavaleta, 2011      NCTsitagliptinglimepiride (add on MET)Low risk of bias -
Aschner, 2010      NCTsitagliptin monotherapymetforminLow risk of bias -
Derosa , 2010     sitagliptin+piometformin+pio -
Goldstein, 2007      NCTsitagliptinplacebonegative
Hanefeld, 2007     sitagliptinplacebonegative
Scott* (sit vs pbo), 2007     sitagliptin 50mg bid monotherapyplacebonegative
Aschner, 2006      NCTsitagliptin monotherapyplacebonegative
Nonaka, 2008      NCTsitagliptin monotherapyplaceboLow risk of bias negative
Raz, 2006     sitagliptin monotherapyplacebonegative
Barzilai, 2011      NCTsitagliptin monotherapyplaceboLow risk of bias -
Mohan , 2009     sitagliptin monotherapyplaceboLow risk of bias -
Chan, 2008     sitagliptin monotherapyplaceboLow risk of bias -
Vilsbøll, 2010      NCTsitagliptinplacebo (add on insulin+/-MET)Low risk of bias -
Charbonnel, 2006      NCTsitagliptinplacebo (add on MET)negative
Nauck, 2007          NCTsitagliptinplacebo (add on MET)negative
Scott** (sit vs pbo on top met), 2007     sitagliptinplacebo (add on MET)negative
raz, 2008      NCTsitagliptinplacebo (add on MET) -
Rosenstock , 2006      NCTsitagliptinplacebo (add on PIO)Low risk of bias -
Rosenstock (sit on top pio vs pbo), 2006      NCTsitagliptinplacebo (on top PIO)suggesting
Hermansen, 2007     sitagliptinplacebo (on-top glimepiride+/- metformine)negative
Rigby , 2010     sitagliptinrosiglitazone (add on MET) -
Al Sifri, 2011     sitagliptinSulphonylurea (on top MET) -
Iwamoto , 2010     sitagliptin monotherapyvogliboseLow risk of bias -
Scott* (sit vs glipi), 2007     sitagliptin 50mg bid monotherapyglipizideLow risk of bias -
Goldstein (sit vs met), 2007     sitagliptinmetformin -
Goldstein (sit+met vs met), 2007     sitagliptinmetformin -
Pérez-Monteverde, 2011      NCTsitagliptinpioglitazoneLow risk of bias -
vildagliptin
NCT00101673      NCTvildagliptin -
Pan, 2008      NCTvildagliptin monotherapyacarboseLow risk of bias -
Foley, 2009      NCTvildagliptin monotherapygliclazideLow risk of bias -
Filozof, 2009      NCTvildagliptingliclazide (add on MET)Low risk of bias -
Matthews , 2010     vildagliptinglimepiride (add on MET)Low risk of bias -
CLAF237A 23104    NCTvildagliptin + METMET -
Schweizer, 2009      NCTvildagliptinmetformin -
Mimori, 2006   vildagliptinplacebo -
Scherbaum [2], 2008          NCTvildagliptinplaceboLow risk of bias negative
Rosenstock, 2008      NCTvildagliptinplaceboLow risk of bias -
NCT00351832    NCTvildagliptinplacebo -
Dejager [1], 2007      NCTvildagliptin monotherapyplaceboLow risk of bias negative
Pi-Sunyer, 2007      NCTvildagliptin monotherapyplaceboLow risk of bias suggesting
Pratley, 2006     vildagliptin monotherapyplaceboLow risk of bias negative
Ristic, 2005     vildagliptin monotherapyplacebonegative
Foley, 2011      NCTvildagliptin monotherapyplacebo -
Kikuchi, 2009     vildagliptin monotherapyplacebo -
Ahren, 2009    NCTvildagliptin monotherapyplacebo -
Lukashevich , 2011     vildagliptinplacebo (add on current therapy) -
Kikuchi, 2010      NCTvildagliptinplacebo (add on glimepiride)Low risk of bias -
Fonseca, 2007      NCTvildagliptinplacebo (add on insulin)Low risk of bias suggesting
Fonseca , 2008     vildagliptinplacebo (add on insulin) -
Ahren, 2004     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2007      NCTvildagliptinplacebo (add on MET)Low risk of bias negative
Goodman, 2009     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2009      NCTvildagliptinplacebo (add on MET) -
NCT00728351    NCTvildagliptinplacebo (add on MET) -
NCT00822211    NCTvildagliptinplacebo (add on MET) -
NCT00494884 (Wollmer)    NCTvildagliptinplacebo (add on MET) -
NCT00396071    NCTvildagliptinplacebo (add on MET) -
Garber, 2008      NCTvildagliptinplacebo (add on SU)Low risk of bias -
Garber, 2007      NCTvildagliptinplacebo (on top pioglitazone)negative
Rosenstock, 2009    NCTvildagliptinrosiglitazoneLow risk of bias -
Ferrannini, 2009      NCTvildagliptinSulfonylurea (add on to MET)Low risk of bias suggesting
GALIANT (Blonde), 2009      NCTvildagliptinTZD (add on MET) -
NCT00368134    NCTvildagliptinvoglibose -
Iwamoto, 2010     vildagliptinvogliboseLow risk of bias -
Schweizer, 2007        NCTvildagliptinmetforminnegative
Goke, 2008     vildagliptinmetformin -
Rosenstock** (vilda vs pio), 2007      NCTvildagliptin monotherapypioglitazoneLow risk of bias -
Bolli, 2008        NCTvildagliptinpioglitazone (add on MET)Low risk of bias negative
Rosenstock** (vilda + pio vs pio), 2007      NCTvildagliptinplacebo (add on TZD)Low risk of bias negative
Rosenstock* (vilda vs rosi), 2007        NCTvildagliptinrosiglitazoneLow risk of bias -